In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecast to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. In this article, we explore three penny stocks that combine balance sheet strength with potential for outsized gains, providing investors a chance to discover hidden value in quality companies.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
WM Technology (MAPS)	$0.326	$62.29M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.11	$343.26M	✅ 3 ⚠️ 2 View Analysis >
FinVolution Group (FINV)	$4.96	$1.23B	✅ 4 ⚠️ 1 View Analysis >
Information Services Group (III)	$3.11	$192.6M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.73	$381.98M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$4.31	$898.36M	✅ 2 ⚠️ 2 View Analysis >
Village Farms International (VFF)	$2.85	$324.59M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$324.55M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.91	$6.54M	✅ 2 ⚠️ 3 View Analysis >

We're going to check out a few of the best picks from our screener tool.

AbCellera Biologics (ABCL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AbCellera Biologics Inc. focuses on discovering and developing antibody-based medicines for unmet medical needs in the United States, with a market cap of approximately $1.16 billion.

Operations: The company's revenue is derived from the discovery and development of antibodies, totaling $75.13 million.

Market Cap: $1.16B

AbCellera Biologics Inc. is navigating the penny stock landscape with a market cap of US$1.16 billion and revenues reaching US$75.13 million, marking growth from prior periods despite ongoing unprofitability and increasing losses over five years. The company remains debt-free, with short-term assets comfortably covering liabilities, providing a cash runway exceeding three years even if cash flow continues to decrease historically by 40.2% annually. Recent announcements include interim results for ABCL635 in Phase 1 trials targeting VMS symptoms associated with menopause, highlighting its potential in advancing antibody therapeutics while maintaining shareholder value without significant dilution recently.

Cytek Biosciences (CTKB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cytek Biosciences, Inc. is a cell analysis solutions company offering tools for biomedical research and clinical applications, with a market cap of approximately $570.76 million.

Operations: The company generates revenue of $201.49 million from its Scientific & Technical Instruments segment.

Market Cap: $570.76M

Cytek Biosciences, Inc. is navigating the penny stock sector with a market cap of US$570.76 million and revenue of US$201.49 million in 2025, despite being unprofitable with increasing losses over five years at 67.6% annually. The company maintains a strong liquidity position, as short-term assets exceed both short-term and long-term liabilities, and it has more cash than total debt, offering a cash runway exceeding three years based on current free cash flow levels. Recent developments include filing a shelf registration for US$28.22 million and setting revenue guidance between US$205 million to US$212 million for 2026.

FinVolution Group (FINV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: FinVolution Group is an investment holding company that operates in the online consumer finance industry across the People’s Republic of China, Indonesia, and internationally, with a market cap of approximately $1.23 billion.

Operations: The company generates revenue of CN¥13.57 billion from its Internet Software & Services segment.

Market Cap: $1.23B

FinVolution Group, with a market cap of $1.23 billion, operates in the online consumer finance sector and has shown stable financial performance despite recent challenges. The company reported annual revenue of CN¥13.57 billion for 2025 and anticipates a slight revenue decline for 2026, ranging from RMB11.5 billion to RMB12.9 billion. Its strong balance sheet features short-term assets exceeding liabilities significantly and cash surpassing total debt levels, indicating robust liquidity management. While earnings growth over the past year was modest at 6.7%, its profit margins have improved slightly, reflecting high-quality earnings amidst industry volatility.

Seize The Opportunity

• Click through to start exploring the rest of the 344 US Penny Stocks now.
• Ready To Venture Into Other Investment Styles? We've found 14 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.